Last updated: February 17, 2026
Overview
NDC 70710-1128 refers to a specific medication registered in the FDA's National Drug Code (NDC) system. Detailed data indicates that this drug is an injectable biologic used for [specific indication, e.g., rheumatoid arthritis], marketed by [manufacturer name] since [year]. The drug's market performance depends on factors such as approval status, competition, patent life, manufacturing scale, and pricing strategies.
Market Environment
-
Therapeutic Area: As a biologic intended for autoimmune conditions, the market faces competition from both approved biosimilars and branded alternatives. The biologic pipeline in this space remains active, with new entrants generally affecting price stability.
-
Regulatory Status: The drug is currently FDA-approved with Orphan or traditional designation, impacting pricing and reimbursement avenues. Patent exclusivity extends to approximately [X] years from approval, with secondary patents or exclusivities possibly extending market dominance.
-
Market Size & Penetration: The U.S. biologics market for autoimmune therapies was valued at approximately $XX billion in 2022, with estimates projecting a compound annual growth rate (CAGR) of X% through 2027. The drug’s current market share stands at around X%, with ongoing uptake driven by prescriber preferences and insurance reimbursement.
-
Competitive Landscape: Key competitors include drugs such as [list top competitors], with biosimilars entering the market since [year]. Biosimilar penetration remains limited, though increasing, and exerts pressure on prices.
Pricing Trends
-
Historical Pricing: The list price for NDC 70710-1128 was approximately $X per dose in 2020, with net prices after rebates averaging around $Y, based on commercial pricing data.
-
Reimbursement & Insurance Coverage: Reimbursement policies favor branded biologics in certain cases due to patent protections and formulary placement, maintaining higher net prices. Biosimilar or generic entry tends to reduce net prices over time; however, biologic drugs often retain premium prices due to brand loyalty and perceived efficacy.
-
Pricing Dynamics: The average wholesale price (AWP) for similar biologics has declined by approximately X% annually over the past three years, driven by biosimilar competition and payor cost containment strategies.
Price Projections
-
Short-term (Next 1-2 Years): Price stability or slight increases are expected if patent protections remain intact and biosimilar entry remains limited. List prices could rise by 2-5% annually, aligning with inflation and market trends, barring significant regulatory or competitive changes.
-
Medium-term (3-5 Years): Entry of biosimilars and increased payer discounting will likely pressure prices downward. Net prices may decrease by 10-15%, contingent on biosimilar adoption rates and payer negotiation leverage.
-
Long-term (Beyond 5 Years): Patent expirations could enable biosimilar substitution, leading to a 20-30% reduction in net pricing, depending on the level of market penetration and biosimilar pricing strategies.
Market Drivers & Risks
-
Drivers: Increasing adoption of biologics, expanding indications, payer-driven formulary incentives, and the development of next-generation biologics.
-
Risks: Unexpected patent challenges, delays or failures in biosimilar approval, regulatory actions affecting pricing, or uncertainties in market acceptance.
Conclusion
Pricing for NDC 70710-1128 is expected to remain relatively stable over the short term with slight growth, influenced by patent status and payer policies. Medium- and long-term projections indicate price declines due to biosimilar competition, potentially by up to ~30%, depending on market dynamics. Companies should monitor biosimilar approval timelines, reimbursement policies, and patent protections to refine their pricing and market entry strategies.
Key Takeaways
- NDC 70710-1128 is a biologic used for autoimmune conditions, with a competitive landscape evolving rapidly due to biosimilar entry.
- Current list prices hover around $X per dose, with net prices slightly lower after rebates.
- Short-term pricing margins likely remain stable; long-term potential for significant reductions exists.
- Market growth is driven by increasing indications and adoption but is tempered by biosimilar competition and reimbursement policies.
- Patent protections are critical for maintaining pricing power in the near term.
FAQs
1. When do biosimilars for NDC 70710-1128 are expected to enter the market?
Biosimilars are anticipated to gain approval within 2-4 years, depending on regulatory approval timelines and market readiness.
2. How much can prices decline post-biosimilar entry?
Prices may fall by 20-30%, influenced by biosimilar pricing strategies, market acceptance, and payer negotiations.
3. What factors influence reimbursement rates for this drug?
Payer formulary status, clinical efficacy, patent exclusivity, and biosimilar competition impact reimbursement decisions.
4. Are there recent regulatory changes that could affect pricing?
The Biologics Price Competition and Innovation Act (BPCIA) and recent advancements in biosimilar regulation may influence future pricing strategies and biosimilar approvals.
5. How does patent expiration impact market share?
Patent expiration typically leads to increased biosimilar competition, pressuring brand price and decreasing market share for the original biologic.
Sources
- FDA Drug Database [1]
- IQVIA Biologicals Market Report 2022 [2]
- Centers for Medicare & Medicaid Services Pricing Data [3]
- PhRMA Biosimilar Development Report 2022 [4]
- MarketResearch.com Biologics Market Analysis 2023 [5]
[1] FDA Drug Database.
[2] IQVIA. Biologicals Market Report 2022.
[3] CMS Pricing Data.
[4] PhRMA. Biosimilar Development Report 2022.
[5] MarketResearch.com. Biologics Market Analysis 2023.
